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INTRODUCTION
Systemic lupus erythematosus (SLE) is a multisystem,chronic, episodic, autoimmune rheumatic disease withcomplex etiology, characterised by immune complexdeposition and autoantibody production mainly anti-nuclear antibodies (ANA). SLE causes immuno-logicallymediated tissue damage that commonly affects the skinand musculoskeletal systems, but can affect every organincluding kidney, central nervous system, heart, lungs.1,2The disease is commonly described in adolescent girlsand adults, but it is believed that 20% of SLE patientshave the onset of disease in their childhood.3 Childhood-onset SLE (cSLE) is a ubiquitous disease, which is
characterised by diverse manifestation of the disease.There is varying epidemiologic information regardingSLE among countries in Asia. Prevalence rate usuallyfalls within 30-50/100,000 population. India, Japan,Saudi Arabia showed a lower prevalence of 3.2-19.3/100,000. Incidence rate as reported from variousstudies, varies from 0.9 to 3.1/100,000 per annum.4
Previous studies have suggested that age at diseaseonset and age at diagnosis may influence diseaseexpression in terms of initial clinical diagnosis, pattern oforgan involvement, and serologic findings.5 Moreover,during recent years a more widespread awareness ofcSLE, as well as the development of newer diagnostictechniques, has led to the recognition that the courseand overall prognosis of cSLE is less grave thanpreviously thought.6 In addition, studies that comparedcSLE with adult-onset SLE (aSLE) demonstrated higherdisease activity and severity in the former group.7Childhood-onset SLE is a more severe disease due tothe higher incidence of nephritis and needs moreaggressive treatment with immunosuppressive agents.8
The studies pertaining to childhood-onset SLE in Pakistanare limited. This study was undertaken to determine thecommon clinical presentations, immunological traits andshort-term outcome in the children who have receivedthe standard care.
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Childhood-Onset Systemic Lupus Erythematosus: A Cohort Study
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ABSTRACT
Objective: To determine the clinical and immunological characteristics and short-term outcome of children with systemiclupus erythematosus (SLE).Study Design: A descriptive cohort study.Place and Duration of Study: Paediatric Rheumatology Clinic, The Aga Khan University Hospital, Karachi, from January2011 to December 2015.Methodology: Clinical and immunological profile and short-term outcome of children less than 16 years of age admittedin the paediatric ward, with the diagnosis of SLE was studied. Demographic data, clinical presentation, laboratory findings,immunological profile and treatment regimens of these children were evaluated.Results: Thirty-two children, satisfying the criteria of American College of Rheumatology (ACR) for SLE, were enrolledduring the study period of five consecutive years. A female predominance was observed with 28 (87.5%) patients beingfemale (F:M 7:1). Mean age at symptom onset was 10.5 +2.7 years; and 8.8 +2.1 years in females and males, respectively.The mean age at diagnosis was 11.3 +2.8 years in females and 9.4 +1.9 years in males. Prolonged fever was the mostcommon non-specific symptom found in 27 (84%), followed by pallor in 13 (41%) patients. Twenty-two (69%) children werefound to be anemic and 18 patients (56%) having signs of arthritis at presentation. Renal involvement was observed in15 (47%) patients. The most common laboratory finding was anemia, found in 22 (69%) of cases. The most commonimmunological markers were serum anti-neutrophil antibodies (ANA), positive in 28 (88%) patients, followed by antidouble-stranded DNA antibodies, raised in 26 (81%) of cases. Out of 32, 12 patients were lost to follow-up. Of theremaining 20 children who were followed for four years, ten (50%) went into remission.Conclusion: Childhood-onset SLE encompasses a wide variety of manifestations with a female preponderance. Fever,arthralgia and pallor are the most frequent clinical manifestations among the children. Hemolytic anemia (HA) is the mostcommon laboratory abnormality, with ANA and anti ds-DNA antibodies positivity in the majority of padiatric patients.
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METHODOLOGY
This cohort descriptive study was carried out on childrenunder the age of 16 years, presenting to the pediatricrheumatology section, The Aga Khan UniversityHospital, Karachi, from January 2011 to December2015, who were diagnosed as SLE. Detailed historyfrom patients and their parents/guardians was taken. Acomplete clinical examination, including musculoskeletalexamination was performed by the treating physician.For the purpose of this study, childhood-onset SLE wasdefined by the presence of any 4 of 11 criteria of theAmerican College of Rheumatology (ACR) used todiagnose SLE in children aged 16 or less (Table I).9Children with other possible, more similar, diagnosessuch as undifferentiated connective tissue disorderwith 3 or few ACR criteria, isolated cutaneous lupuserythematosus, neonatal lupus erythematosus, drug-induced lupus, and other autoimmune diseases wereexcluded.
A retrospective review of files was done and informationwas collected via a structured proforma prepared for thestudy. Data pertaining to gender, age at onset ofsymptoms and age at diagnosis, systems and organinvolvement were collected. Laboratory parametersincluding hematological findings, e.g. hemoglobin,leucocytes, platelets, inflammatory markers, erythrocytesedimentation rate (ESR) and C-reactive protein (CRP),presence or absence of immunological indicators likeanti-nuclear antibody (ANA), extractable nuclear antigen(ENA), double stranded DNA (ds-DNA) were collected.Pathological findings, including the renal biopsy resultsin children with lupus nephritis were also noted. Inaddition, different therapeutic regimen offered to thesechildren and their short-term response was alsoobserved.
Data were entered, validated and analysed usingStatistical Package for Social Sciences (SPSS) version19.0. Mean and standard deviation were expressed fornumerical variables, while frequencies and percentageswere expressed for categorical variables. As per EthicalReview Committee (ERC) guidelines, the study protocolwas granted exemption (1935-Ped-ERC-11).
The Chi-square test was applied with the p-value of<0.005 being taken as statistically significant.
RESULTS
A total of 32 patients were enrolled during the studyperiod of five consecutive years. A female predominancewas observed, 28 (87.5%) of the patients being females(F:M 7:1). Mean age of onset of symptoms varied amongmales and females.
Mean age at symptom onset was 10.5 +2.7 years, and8.8 +2.1 years in females and males, respectively. Themean age at diagnosis was 11.3 +2.8 years in femalesand 9.4 +1.9 years in males. Consanguinity was presentamong 15 47% of the parents of the patients.
Prolonged fever was the most common non-specificpresenting symptom in a majority of the children.Prolonged fever presented in 27 (84%) children followedby pallor in 13 (41%), and anorexia and fatigue in 10(31%) each. Other symptoms included alopecia (n=10,31%), weight loss (n=9, 28%) and myalgia (n=8, 25%).
The most common specific clinical manifestation in thesechildren, based on the ACR criteria for the diagnosis ofSLE, was anemia, which was present in 22 (69%)patients. Arthritis is the second common manifestationafter anemia; 18 (56%) patients have polyarthritis atpresentation, large joints mainly knee, ankle, wrist andelbow joints are involved in most of the patients. Malarrash was found in eight (25%) patients whilephotosensitivity and discoid rash were seen in 3 (9%).Ten (31%) patients had muco-cutaneous ulcers atpresentation. Renal involvement was observed in15 (47%) patients who presented with hematuria,proteinuria, edema and hypertension. Nine of them, whohad heavy proteinuria, underwent renal biopsy. Five(16%) patients exhibited neuropsychiatric symptoms; outof which, two had new onset seizures, two hadpsychosis; while one already had seizure disorderwhose symptoms were exacerbated with the onset ofthe disease. Pericardial effusion was found in four(12.5%) patients, out of which one required peri-cardiocentesis due to cardiac de-compensation.
Various laboratory parameters in patients with SLE areshown in Table II. Anemia (hemoglobin <10 g/dl) was themost frequent hematological abnormality observed in22 patients (69%); out of which 13 (41%) patients wereseverely anemic (Hb <6 gm/dl) and required urgenttransfusion of packed RBC's. Direct coombs waspositive in 18 (56%) who had evidence of hemolysis withraised reticulocyte count. The remaining had microcytichypochromic anemia. Leucopenia (white cell counts<4,000/mm3) was seen in 7 (22%) patients; 12 (37%)had thrombocytopenia (platelet count <150,000/mm3) atadmission. It was observed that acute phase reactants,including ESR and CRP, were also raised in most of thepatients with the frequency of 25 (78%) and 22 (69%),respectively. Low serum complements C3 & C4 wereobserved in 25 (78%) and 11 (34%) patients, respectively.Immunological markers demonstrated that overall28 (88%) patients had ANA positivity, followed by antids-DNA in 26 (81%) children; anti smith antibody waselevated in 11 (34%) children. Laboratory and immuno-logical profile is summarised in Table II.
Out of 15 patients who presented with renal manifestations,nine underwent renal biopsy. A majority of them (six),were of WHO class IV, while three were of class I, III andV each. Class III was treated with azathioprine, andclass V with cyclosporine. Patients with class IVreceived monthly cyclophosphamide infusion for aperiod of seven months followed by quarterly infusion for
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two and half years. Mycophenolate mofetal was used inpatients who refused the cyclophosphamide infusion.
Several anti-inflammatory and immunosuppressantdrugs were given to these children. Majority (91%) weretreated with hydroxychloroquine. The other commonlyprescribed drugs were steroids and NSAIDS given in88% and 75% children, respectively. Immunosuppressivelike cyclophosphamide, azathioprine and mycophenolatemofetal were used in children with lupus nephritis andwith neurological manifestations. Other therapeuticmeasures included blood transfusion in 41% andanticonvulsant medication in 9% of the children.
Out of 32 patients, 20 (62.5%) were followed for 4 years(Figure 1). Twelve patients (37.5%) were lost to follow-up due to certain reasons, the major one being due tolack of accessibility as they were from the remote areas.Other reasons included prolonged nature of therapy andfinancial constraints.
During the follow-up period, out of 20 patients, 10 (50%)patients showed a good response to therapy and were inclinical and biochemical remissions. Five (25%) children,who had lupus nephritis, had active disease and were ontreatment. Five (25%) children died during the therapy;two of them due to disseminated tuberculosis, onebecause of chronic renal insufficiency and two diedbecause of severe sepsis.
DISCUSSION
There is compelling evidence that the presentation ofchildhood SLE (cSLE) is not only diversified in terms ofdisease manifestations, but it tends to be more serious,with renal involvement, and is associated with a moreaggressive clinical course and an increased need forheavy immunosuppressive therapy.2,10-12
In this descriptive observational study, the authors foundthat the prevalence of cSLE is quite high in the femalepopulation, with a female to male ratio of 7:1, which isnearly similar to most previous reports on cSLE.5,7,13,14
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Table I: ACR criteria for diagnosing SLE.
ACR criteria
Malar rash
Discoid rash
Serositis; pleuritis, pericarditis 
Oral ulcers
Arthritis; non-erosive
Photosensitivity
Neurological disorders; seizure, psychosis 
Blood disorders; hemolytic anemia, leucopenia, lymphopenia,
Renal disease; proteinuria, RBC casts 
Positive antinuclear antibodies
Immunological abnormalities (positive anti ds-DNA, anti-Sm, etc.) 
Table II: Laboratory and immunological profile of children with c-SLE.
Laboratory results Number (%)
Leokopenia (<4,000/mm3) 7 (22)
Anti-SM 11 (34)
Serum complement C3 11 (34)
Thrombocytopenia (<150,00/ mm3) 12 (37)
Coombs (positive) 18 (56)
Anemia (HB <10g/dl) 22 (69)
Elevated CRP 22 (69)
Serum complement C3 25 (78)
ESR (>20 mm/hr) 25 (78)
Anti DS-DNA 26 (81)
ANA 28 (88)
Table III: Comparative analysis of our study and two multicenter studies.
Variables The present Brazilian French study multicenter study18 multicenter study19(n=32) (n=847) (n=155)Percent Percent *¥ Percent Ý
Demographic data
Gender
Female 87.5 84
Male 12.5 16
Mean age of diagnosis (years) 10.35 9.35 11.5
Non-specific symptoms
Fever 84 62 60
Weight loss 28 27 -
Clinical manifestations, based on ACR criteria
Arthritis 56 68 62
Malar rash 25 54 39
Discoid rash 9 7 6.5
Photosensitivity 9 42 13
Oral ulcers 31 32 10.5
Serositis 12.5 30 -
Renal disorders 47 51 58
Neurological symptoms 16 28 20
Laboratory findings
Hemolytic anemia 69 20 27
Leukopenia 22 23 35
Thrombocytopenia 37 14 28
Immunological profiles
ANA 88 99 97
Anti ds-DNA 81 67 93
Anti-Sm 34 38 32
* Mean of the percentages in the three age groups ranging from <2 years till <18 years.¥ Represented white (patients with white European ancestors), African-Latin Americans(patients born in Latin America with at least 1 African ancestor), Asian (patients with Asianancestors), and other/unknown.Ý Represented white, black, or North African children, but was significantly higher number ofAsian children.
Figure 1: Follow-up results of the studied cohort of children with SLE.
Males present early as compared to females; meanage at onset of disease in males was 8.8 +2.1 yearscompared to females whose mean age was 10.5 +2.7years. In addition, we observed that fever and pallorwere the most common non-specific manifestations.Furthermore, we also observed the high frequency ofrenal manifestations in our population. Most of theprevious studies have underlined the frequent anddebilitating involvement of renal pathology in cSLE.6,8,15-17Coomb's positive hemolytic anemia was the mostcommon laboratory derangement; whereas, ANApositivity followed by anti ds-DNA elevation were themost frequent immunologic findings.
A comparative analysis of two multicenter studies onclinical features, organ involvement, laboratory andimmunologic profile of c-SLE patients showedcomparable results with minor contrasts with this studyas shown in Table III.18,19
In addition to the age at onset of the disease, inter-ethnicdifferences have also influenced the disease course inthe pediatric population. Mortality is higher in certainracial and ethnic groups,20 including poorer prognosis inAfrican-American and Hispanic patients. Severe nephro-pathy is significantly more frequent in Asian patients.21
Arthritis and fever were the two most common mani-festations, in all ethnicities including American, African,European and Asian; as evidenced in other multicenterstudies.22 However, this study results had significantdifferences in frequencies of other manifestations ascompared to these multicenter cohorts in different races.Malar rash has occurred in around 58 to 60% ofAmerican and European children and is the one of themost common manifestations at the time of presentation.23
Similarly, hemolytic anemia (HA) was found to be themost common laboratory abnormality in up to 69% (22children), which is quite close to occurrence of HA aspart of cSLE in African children in 82%, compared to only20% and 27% children of American and Europeandescent.5,21
Although the racial difference had presented withsubstantial variation in symptomatology and laboratoryfindings, immunological profiling did not reveal suchremarkable disparities. ANA is positive in up to 88% ofpatients in this study and analogous results have beendemonstrated in children of all other races and rangefrom 92-99%.4,5,21 Anti ds-DNA antibodies did not showcomparable results among different ethnicities withpositivity in 81% in this study; whereas, it was foundpositive in up to 67% and 85-95% in American andEuropean ancestry.21
A comparison of cSLE between this study and an Indianseries showed analogous findings representing diseaseprogression in Asian population.24
Limitations of the study include small sample size andsingle center study.
Strength of the study is that it is among the few reportedstudies from the region and can be used as a parentstudy to explore the disease further. In addition, owing tothe rarity of SLE overall and especially in the pediatricpopulation, we did not come across any comparativework done on cSLE in Pakistan.
CONCLUSION
Childhood-onset SLE encompasses a wide variety ofmanifestations with a greater female preponderance. Itis associated with an aggressive disease course ascompared to adult SLE. Biopsy proven lupus nephritis isthe most common complication reported. Hemolyticanemia is the most common laboratory derangementand ANA and anti ds-DNA are positive in the majority ofc-SLE patients. A detailed history, thorough review ofsystems, complete physical examination, completeblood count, urinalysis, and a high index of suspicionhelp make the correct diagnosis of SLE in patients. Earlydiagnosis and early treatment can improve theprognosis of children with SLE.
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